logo-loader

Horizon Discovery inks new collaboration

Published: 07:38 06 Sep 2016 BST

genomics_57ce6cb08c8dc
The US start-up will use Horizon's cutting edge technology in research.

Gene editing specialist Horizon Discovery Group PLC (LON:HZD) has been recruited by Fulcrum Therapeutics Inc to deploy its cutting-edge CRISPR-based screening platform to identify targets for regulating gene expression.

The Horizon technology will be used to help uncover treatments for rate genetic diseases.

Initially the pair will collaborate on two programmes. However the tie-up may be extended.

"CRISPR-based screening promises to be a powerful tool for the identification of novel targets and the collaboration with Fulcrum demonstrates the potential for this technology to be used in areas outside of oncology," said Horizon chief executive, Dr Darrin Disley.

"This partnership confirms Horizon's role as a preferred partner not only for established biotechnology and pharmaceutical companies, but also for start-ups looking for long-term collaborations rather than having to build in-house capabilities."

Acquisition gives Horizon Discovery a 'full and complete suite of tools' to...

Chris Claxton, VP Investor Relations & Corporate Communications at Horizon Discovery Group PLC (LON:HZD), discusses with Proactive their 'transformational' acquisition of GE healthcare business Dharmacon. The US$85mln deal was announced in July and funded through cash and shares and...

on 4/9/17